An Open-Label Extension Study of Reslizumab 110-mg Fixed, Subcutaneous Dosing in Patients 12 Years of Age and Older With Severe Eosinophilic Asthma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 02 Nov 2017
At a glance
- Drugs Reslizumab (Primary)
- Indications Asthma
- Focus Adverse reactions
- Sponsors Teva Branded Pharmaceutical Products R&D
- 30 Oct 2017 Planned End Date changed from 5 Sep 2018 to 3 Oct 2018.
- 30 Oct 2017 Planned primary completion date changed from 31 Aug 2017 to 5 Sep 2018.
- 30 Oct 2017 Status changed from recruiting to active, no longer recruiting.